research use only
Cat.No.S2284
| Related Targets | CDK HSP PD-1/PD-L1 ROCK Wee1 DNA/RNA Synthesis Ras KRas Aurora Kinase Casein Kinase |
|---|---|
| Other Microtubule Associated Inhibitors | Nocodazole Patupilone (Epothilone B) CW069 Combretastatin A4 Lexibulin (CYT997) Epothilone A ABT-751 (E7010) Cucurbitacin B TRx0237 (LMTX) mesylate DM1 (Mertansine) |
|
In vitro |
DMSO
: 80 mg/mL
(200.28 mM)
Ethanol : 80 mg/mL Water : 79 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 399.44 | Formula | C22H25NO6 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 64-86-8 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Colchineos, Colchisol, Colcin,NSC 757 | SMILES | CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC | ||
Read more about storage stability stock solution CAS number SMILES
| In vitro |
Colchicine is a tubulin inhibitor and a microtubule disrupting agent, which inhibits the tubulin polymerization on the site of β-tubulin. |
|---|---|
| In vivo |
Colchicine prevents NSAID-induced small intestinal injury by inhibiting activation of the NLR family pyrin domain-containing 3 (NLRP3) inflammasome. |
References |
(data from https://clinicaltrials.gov, updated on 2026-07-08)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06352632 | RECRUITING | Stroke |
The George Institute |
2024-09-26 | PHASE3 |
| NCT07232069 | RECRUITING | Coronary Artery Disease Risk Factors Multiple; Coronary Artery Disease Progression; Prevention & Control; Premature Atherosclerosis |
Duke University |
2026-07-21 | PHASE3 |
| NCT06930885 | RECRUITING | Atherothrombotic Diseases; Atherosclerotic Cardiovascular Disease (ASCVD) |
Hospital do Coracao |
2025-06-12 | PHASE3 |
| NCT05949281 | ACTIVE_NOT_RECRUITING | Type 1 Diabetes; Cardiovascular Diseases; Chronic Inflammation |
Asger Lund, MD |
2023-08-29 | PHASE2 |
| NCT06855433 | RECRUITING | CPPD - Calcium Pyrophosphate Deposition Disease |
Brigham and Women's Hospital |
2026-07-20 | PHASE2 |
| NCT07349875 | RECRUITING | Coronary Artery Disease (CAD) |
Nanjing First Hospital, Nanjing Medical University |
2026-01-01 | PHASE4 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.